Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MACUGEN

« Back to Dashboard
Macugen is a drug marketed by Valeant Pharms Llc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has three hundred and sixty-seven patent family members in thirty-six countries.

The generic ingredient in MACUGEN is pegaptanib sodium. One supplier is listed for this compound. Additional details are available on the pegaptanib sodium profile page.

Summary for Tradename: MACUGEN

Suppliers / Packagers: see list1

Pharmacology for Tradename: MACUGEN

Clinical Trials for: MACUGEN

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
Status: Completed Condition: Proliferative Diabetic Retinopathy; Diabetic Macular Edema

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Status: Completed Condition: Branch Retinal Vein Occlusion

Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Status: Completed Condition: Diabetic Macular Oedema

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
Status: Completed Condition: Exudative Age-related Macular Degeneration

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
Status: Terminated Condition: Cystoid Macular Edema

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Status: Recruiting Condition: Age-related Macular Degeneration

A Pilot Study for the Treatment of Iris Neovascularization With Macugen
Status: Completed Condition: Iris Neovascularization; Diabetic Retinopathy

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Status: Active, not recruiting Condition: Proliferative Diabetic Retinopathy

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Status: Completed Condition: PDR

Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
Status: Recruiting Condition: Age-Related Macular Degeneration; Retinal Vein Occlusion; Diabetic Macular Edema

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYes6,051,698<disabled>Y <disabled>
Valeant Pharms Llc
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYes6,011,020<disabled>Y <disabled>
Valeant Pharms Llc
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYes5,932,462<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MACUGEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,331,394 Nucleic acid ligands to integrins<disabled in preview>
6,613,526 Systematic evolution of ligands by exponential enrichment: tissue selex<disabled in preview>
6,569,620 Method for the automated generation of nucleic acid ligands<disabled in preview>
6,458,539 Photoselection of nucleic acid ligands<disabled in preview>
7,196,069High affinity RNA ligands of basic fibroblast growth factor<disabled in preview>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MACUGEN

Country Document Number Publication Date
Australia8206191Jan 07, 1992
Germany69535365Feb 22, 2007
Denmark0533838Feb 23, 1998
Spain2426160Oct 21, 2013
Japan2007195560Aug 09, 2007
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn